Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 14/20 | 0.76 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.76 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.64 |
| ▸ | RAF1 | P04049 | 1/20 | 0.64 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.64 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8321544 | 0.88 | GCGR (0.67) | GCGRMAPK14 | |
| SCHEMBL2662559 | 0.87 | GCGR (1.00) | GCGRMAPK14MAPK13RAF1MAPK9 | |
| SCHEMBL6586611 | 0.86 | GCGR (0.86) | GCGRMAPK14 | |
| SCHEMBL2647604 | 0.81 | GCGR (1.00) | GCGRMAPK14 | |
| SCHEMBL2647609 | 0.77 | GCGR (0.79) | GCGRMAPK14MAPK13RAF1MAPK8 | |
| SCHEMBL8680959 | 0.77 | GCGR (0.79) | GCGRMAPK14 | |
| SCHEMBL21557189 | 0.77 | GCGR (1.00) | GCGRMAPK14MAPK13RAF1MAPK8 | |
| SCHEMBL2647090 | 0.75 | MAPK14 (0.75) | GCGRMAPK14MAPK13RAF1MAPK8 | |
| SCHEMBL8119445 | 0.75 | MAPK14 (0.75) | GCGRMAPK14MAPK13RAF1MAPK8 | |
| SCHEMBL13130596 | 0.75 | MAPK14 (0.75) | GCGRMAPK14MAPK13RAF1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198730-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | claimed |
| EP-1432699-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-30 | — | — | EP | claimed |
| WO-2003022832-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | claimed |
| US-7446106-B2 | Pyridylfurans and pyrroles as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20040198730-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1432699-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003022832-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198730-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | BRAF, ARAF, RAF1 | GCGR 2587/4885MAPK14 119/4885MAPK13 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.